News from daiichi sankyo, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 08, 2014, 07:09 ET

Daiichi Sankyo Launches New Formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it has launched a new formulation of LIXIANA® 60 mg...

Dec 04, 2014, 16:40 ET

Ambit Biosciences and Daiichi Sankyo, Inc. Announce Two Oral Presentations And One Poster Highlighting Quizartinib To Be Presented At The 56th Annual Meeting Of The American Society Of Hematology (ASH)

Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and...

Nov 10, 2014, 19:37 ET

Daiichi Sankyo and Ambit Announce Results of Tender Offer

Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences Corporation (hereinafter, Ambit Biosciences)...

Oct 30, 2014, 20:08 ET
Oct 14, 2014, 16:43 ET

Announcement Regarding Submission of Tender Offer for Shares in Ambit Biosciences Corporation

 On Friday October 10, U.S. Eastern Time, Daiichi Sankyo Company, Limited (hereinafter, Daiichi Sankyo) (TSE: 4568), through its wholly-owned...

Sep 29, 2014, 18:28 ET
Daiichi Sankyo Company, Ltd. (PRNewsFoto/Daiichi Sankyo Company, Ltd.)

Daiichi Sankyo va acquérir Ambit Biosciences

-- Le composé chimique phare, le Quizartinib, va renforcer le portefeuille de traitements cancérologiques de Daiichi Sankyo Daiichi...

Sep 29, 2014, 13:03 ET
Daiichi Sankyo Company, Ltd. (PRNewsFoto/Daiichi Sankyo Company, Ltd.)

Daiichi Sankyo adquiere Ambit Biosciences

-- El principal compuesto, quizartinib, construirá la gama de oncología de Daiichi Sankyo Daiichi Sankyo Company, Ltd. (de...

Sep 29, 2014, 12:50 ET
Daiichi Sankyo Company, Ltd. (PRNewsFoto/Daiichi Sankyo Company, Ltd.)

Daiichi Sankyo wird Ambit Biosciences übernehmen

-- Leitwirkstoff Quizartinib kommt dem weiteren Ausbau der Onkologie-Pipeline von Daiichi Sankyo zugute Daiichi Sankyo Company, Ltd....

Sep 28, 2014, 19:07 ET
Daiichi Sankyo Company, Ltd. (PRNewsFoto/Daiichi Sankyo Company, Ltd.)

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo Company, Ltd. (hereinafter Daiichi Sankyo) (TSE: 4568) and Ambit Biosciences (NASDAQ: AMBI), jointly announced today that they have...

Sep 26, 2014, 07:00 ET

Daiichi Sankyo Receives Approval for Additional Indications of LIXIANA® (edoxaban) in Japan

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that it received approval from the Ministry of Health, Labour and...

Sep 03, 2014, 07:47 ET

Daiichi Sankyo utvider TaNeDS Collaborative Drug Discovery-programmet i Europa

TOKYO, 1 september 2014 /PRNewswire/ - Daiichi Sankyo Company, Limited (Tokyo-børsen: 4568, heretter Daiichi Sankyo) kunngjorde 1....

Sep 03, 2014, 03:04 ET

Daiichi Sankyo öffnet kollaboratives Arzneimittelforschungsprogramm TaNeDS in Europa für weitere Länder

Daiichi Sankyo Company Limited (Tokioter Börse: 4568; im Folgenden „Daiichi Sankyo") veröffentlichte am 1. September nähere...

Sep 03, 2014, 03:03 ET

Daiichi Sankyo amplía el programa colaborador de descubrimiento de fármacos TaNeDS en Europa

Daiichi Sankyo Company, Limited (Bolsa de Valores de Tokio: 4568; de aquí en adelante Daiichi Sankyo), anunció el 1 de septiembre los...

Sep 02, 2014, 11:50 ET
PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF)

One Year Data from the PREFER in AF Registry Show Significant Changes in Atrial Fibrillation (AF) Management in Europe and Implementation of Clinical Guidelines

Registry provides new insights into AF treatment decisions, including patients' quality of life and treatment satisfaction[1],[2] ESC...

Sep 02, 2014, 09:00 ET

Subgroup Analysis of ENGAGE AF-TIMI 48 Explores the Relationship Between Edoxaban Dose, Concentration, Anti-Factor Xa Activity and Outcomes

 Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced data from a subgroup analysis of the phase 3 ENGAGE AF-TIMI 48...

Sep 02, 2014, 08:57 ET

Daiichi Sankyo étend son programme collaboratif de découverte médicamenteuse TaNeDS en Europe

Daiichi Sankyo Company, Limited (Bourse de Tokyo : 4568 ; ci-après désignée Daiichi Sankyo) a annoncé le 1er...

Aug 31, 2014, 22:00 ET

Daiichi Sankyo Further Expands TaNeDS Collaborative Drug Discovery Program in Europe

Daiichi Sankyo Company, Limited (Tokyo Stock Exchange: 4568; hereafter Daiichi Sankyo) announced on September 1 details of the application for its...

Aug 31, 2014, 08:38 ET

Global Survey of Cardiologists Highlights Complexity of Managing Non-Valvular Atrial Fibrillation and Reinforces Need for Individualized Approach to Patient Care

Daiichi Sankyo and the Heart Rhythm Society today announced results from a global survey, which polled cardiologists from around the world and...

Aug 06, 2014, 19:00 ET
Daiichi Sankyo Logo. (PRNewsFoto/Daiichi Sankyo, Inc.)

Daiichi Sankyo and Charleston Laboratories Announce Collaboration to Develop and Commercialize Novel, Fixed-Dose Combination Hydrocodone Products for Pain and Opioid-Induced Nausea and Vomiting (OINV) in the US

Daiichi Sankyo and Charleston Laboratories, Inc., through its wholly owned subsidiary LOCL Pharma, Inc., announced today that the parties have...

May 16, 2014, 07:33 ET

Journée Mondiale de l'Hypertension 2014 : Daiichi Sankyo fait du bien à votre cœur !

  - La Journée Mondiale de l'Hypertension a lieu chaque année le 17 mai. Le thème choisi pour 2014 est "Connaître...